Thursday May 25th 2017

Archive for June, 2016

Treatment for IBS proves difficult, survey reveals

Treatment for IBS proves difficult, survey reveals

A new national survey by Health Union of more than 1,000 individuals with Irritable Bowel Syndrome (IBS) reveals that the condition is difficult to diagnose and often even more difficult to treat. [Read More]

New Study Provides More Evidence That Obesity Increases Risk for Developing MS

New Study Provides More Evidence That Obesity Increases Risk for Developing MS

/About-the-Society/News/New-Study-Provides-More-Evidence-That-Obesity-Incr [Read More]

New technology could help deliver treatments for brain injuries

New technology could help deliver treatments for brain injuries

A new study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute describes a technology that could lead to new therapeutics for traumatic brain injuries. The discovery, published today in Nature Communications, provides a means of homing drugs or [Read More]

 Page 1 of 17  1  2  3  4  5 » ...  Last » 

Latest Topics

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Hospitals vary widely in how often they transition people with strokes from active treatment to comfort or hospice care [Read More]

Roche investigating case of patient illness after taking MS drug

Roche investigating case of patient illness after taking MS drug

ZURICH (Reuters) - A person in Germany treated with Roche ’s new multiple sclerosis drug Ocrevus has been diagnosed [Read More]

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]